Company Description
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services.
In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations.
The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jan 16, 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Ted Karkus |
Contact Details
Address: 711 Stewart Avenue, Suite 200 Garden City, New York 11530 United States | |
| Phone | 215 345 0919 |
| Website | prophaselabs.com |
Stock Details
| Ticker Symbol | PRPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000868278 |
| CUSIP Number | 74345W108 |
| ISIN Number | US74345W1080 |
| Employer ID | 23-2577138 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ted William Karkus | Chairman and Chief Executive Officer |
| Jed A. Latkin | Chief Operating Officer and Head of Finance Department |
| Sergio Miralles | Executive Vice President and Chief Information Officer |
| Kamal Obbad | Senior Vice President and Director of Sales and Marketing - Nebula Genomics |
| Jason Karkus | President of Nebula Genomics |
| Lance Bisesar | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | EFFECT | Notice of Effectiveness |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 8, 2024 | 424B5 | Filing |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | FWP | Free Writing Prospectus |
| Nov 7, 2024 | 424B5 | Filing |